Form4insider filings, from the source

SEC Form 4 · accession 0001567619-18-007788

Loxo Oncology, Inc. · LOXO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jacob Van Naarden
Officer — Chief Business Officer
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001581720

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockDec 10, 2018M4,500$13.67A18,200D
Common StockF2,F3Dec 10, 2018S400$130.59D17,800D
Common StockF2,F4Dec 10, 2018S1,000$132.23D16,800D
Common StockF2,F5Dec 10, 2018S900$133.17D15,900D
Common StockF2,F6Dec 10, 2018S1,400$134.65D14,500D
Common StockF2,F7Dec 10, 2018S500$135.14D14,000D
Common StockF2,F8Dec 10, 2018S200$136.48D13,800D
Common StockDec 10, 2018S100$137.39D13,700D
Common StockDec 11, 2018M4,500$13.67A18,200D
Common StockF2,F9Dec 11, 2018S400$134.74D17,800D
Common StockF2,F10Dec 11, 2018S800$135.92D17,000D
Common StockF2,F11Dec 11, 2018S1,759$137.09D15,241D
Common StockF2,F12Dec 11, 2018S500$137.73D14,741D
Common StockF2,F13Dec 11, 2018S500$139.23D14,241D
Common StockF2,F14Dec 11, 2018S541$140.16D13,700D
Common StockDec 11, 2018M7,000$3.648A20,700D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F15$13.67Dec 10, 2018M4,500D—Dec 18, 2024Common Stock4,50083,443D
Employee Stock Option (Right to Buy)F15$13.67Dec 11, 2018M4,500D—Dec 18, 2024Common Stock4,50078,943D
Employee Stock Option (Right to Buy)F16$3.648Dec 11, 2018M7,000D—Jun 18, 2024Common Stock7,00033,326D

Explanation of responses